Enables ATP hydrolysis activity and TBP-class protein binding activity. Involved in positive regulation of inclusion body assembly and regulation of AMPA receptor activity. Located in inclusion body and synaptic vesicle. Part of cytosolic proteasome complex; nuclear proteasome complex; and proteasome accessory complex. Orthologous to human PSMC5 (proteasome 26S subunit, ATPase 5); PARTICIPATES IN retinoic acid signaling pathway; ubiquitin/proteasome degradation pathway; INTERACTS WITH 1,1,1-Trichloro-2-(o-chlorophenyl)-2-(p-chlorophenyl)ethane; 1,2,4-trimethylbenzene; 17alpha-ethynylestradiol.
[Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of PSMC5 mRNA; Nicotine inhibits the reaction more ...
[Caffeine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of PSMC5 mRNA; [Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] more ...
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with more ...
[Caffeine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of PSMC5 mRNA; Caffeine inhibits the reaction more ...
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with more ...
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with more ...
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with more ...
[Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of PSMC5 mRNA; Nicotine inhibits the reaction more ...
[perfluorohexanesulfonic acid co-treated with perfluorooctanoic acid co-treated with perfluorooctane sulfonic acid co-treated with perfluoro-n-nonanoic acid more ...
[perfluorohexanesulfonic acid co-treated with perfluorooctanoic acid co-treated with perfluorooctane sulfonic acid co-treated with perfluoro-n-nonanoic acid more ...
[perfluorohexanesulfonic acid co-treated with perfluorooctanoic acid co-treated with perfluorooctane sulfonic acid co-treated with perfluoro-n-nonanoic acid more ...
[perfluorohexanesulfonic acid co-treated with perfluorooctanoic acid co-treated with perfluorooctane sulfonic acid co-treated with perfluoro-n-nonanoic acid more ...
[perfluorohexanesulfonic acid co-treated with perfluorooctanoic acid co-treated with perfluorooctane sulfonic acid co-treated with perfluoro-n-nonanoic acid more ...
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with more ...
Multiple mammalian proteasomal ATPases, but not proteasome itself, are associated with TATA-binding protein and a novel transcriptional activator, TIP120.
Differential ligand-dependent interactions between the AF-2 activating domain of nuclear receptors and the putative transcriptional intermediary factors mSUG1 and TIF1.